The present specification relates to a double spiro structure compound, and an organic light emitting device comprising the same.

Novel phosphorescent metal complexes containing ligands having the Formula I: ##STR00001##
bearing either a naphthalene or other fused heterocycle moieties such as benzofuran and benzothiophene useful as emitters in OLEDs and improve the device efficiency and the FWHM of the emission.

Novel phosphorescent metal complexes containing ligands having the Formula I: ##STR00001##
bearing either a naphthalene or other fused heterocycle moieties such as benzofuran and benzothiophene useful as emitters in OLEDs and improve the device efficiency and the FWHM of the emission.

A heterocyclic compound represented by Formula 1 and an organic electroluminescence device including the same in an emission layer. ##STR00001## In Formula 1, Z is represented by Formula 2-1 or 2-2. ##STR00002## In Formula 2-2, X.sub.1 to X.sub.3 are each independently CR.sub.10 or N, and at least one of X.sub.1 to X.sub.3 is N.

A heterocyclic compound represented by Formula 1 and an organic electroluminescence device including the same in an emission layer. ##STR00001## In Formula 1, Z is represented by Formula 2-1 or 2-2. ##STR00002## In Formula 2-2, X.sub.1 to X.sub.3 are each independently CR.sub.10 or N, and at least one of X.sub.1 to X.sub.3 is N.

The present disclosure relates to bifunctional compounds, which find utility to degrade (and inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.

The present disclosure relates to bifunctional compounds, which find utility to degrade (and inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.

The present disclosure relates to bifunctional compounds, which find utility to degrade (and inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.

The present disclosure relates to bifunctional compounds, which find utility to degrade (and inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.

The disclosure relates to aryl hydrocarbon receptor antagonists as well as methods of modulating aryl hydrocarbon receptor activity and expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presence of these agents. Additionally, the disclosure provides methods of treating various pathologies, such as cancer, by administration of these aryl hydrocarbon receptor antagonists. Additionally, the disclosure provides methods of treating various pathologies in a patient by administration of expanded hematopoietic stem cells. The disclosure further provides kits containing aryl hydrocarbon receptor antagonists that can be used for the expansion of hematopoietic stem cells. The disclosure further relates to pharmaceutical compositions comprising the compounds and methods of treating or preventing a disease in which aryl hydrocarbon receptor plays a role.